WEIR monoclonal antibody contract

The Food and Drug Administration is seeking to acquire strain-specific monoclonal antibodies for the development of alternative potency assays for pandemic influenza vaccines under a forecasted contract identified by NAICS code 541714. These antibodies are critical for advancing testing methodologies that ensure vaccine efficacy and consistency during public health emergencies, particularly when traditional assays may be insufficient or delayed. The initiative is managed by the Center for Biologics Evaluation and Research, with the Program Point of Contact listed as Cber Acquisition Liaison at cberacquisitions@fda.hhs.gov, while the Contracting Officer position remains undetermined. The opportunity is publicly forecasted with no set-aside designation and no specified place of performance or location details, indicating early-stage planning. All formal acquisition activities will follow the public posting on the HHS OSDBU portal, with a posted date of May 25, 2026.